title: Nonalcoholic Fatty Liver Disease.
abstract: Nonalcoholic fatty liver disease (NAFLD), the hepatic manifestation of the metabolic syndrome, is the leading cause of chronic liver disease. Treatments target lifestyle modification and improvement of underlying risk factors. Noninvasive biomarkers for diagnosis and staging of NAFLD and safe, cost-effective treatments for patients with nonalcoholic steatohepatitis (NASH) and/or NASH-related cirrhosis are currently under investigation.
authors.affiliation: clinical trials assistant, Division of Gastroenterology and Hepatology, Department of Medicine, Duke University, Durham, North Carolina.
authors.forename: Tyler
authors.initials: T
authors.lastname: Thrasher
authors.affiliation: associate professor of medicine, Division of Gastroenterology and Hepatology, Department of Medicine, Duke University, Durham, North Carolina manal.abdelmalek@duke.edu.
authors.forename: Manal F
authors.initials: MF
authors.lastname: Abdelmalek
mesh_terms: D006801:Humans; D065626:Non-alcoholic Fatty Liver Disease / Q000175:diagnosis / Q000188:drug therapy*